iCellate Medical discontinues direct-to-consumer sales of its GeneMate® service

Stockholm, Sweden – July 6, 2023 - iCellate Medical discontinues D2C sales of its GeneMate® service. GeneMate® combines DNA sequencing with an analysis of family cancer history to provide a comprehensive assessment of an individual’s hereditary cancer risk. The service will be discontinued as the company focuses its resources on its CellMate® platform for detection and analysis of circulating tumor cells (CTCs). CellMate® is developed for early cancer detection and precision diagnostics.GeneMate® has primarily been marketed directly to consumers in Sweden and the UK since its launch in 2021,